[Skip to Content]
[Skip to Content Landing]
Views 3,494
Citations 0
Medical News & Perspectives
July 16, 2014

New Practice-Changing Study Findings Presented at ASCO

JAMA. 2014;312(3):218-219. doi:10.1001/jama.2014.7708

Chicago—Phase 3 clinical trial results reported at the annual meeting of the American Society of Clinical Oncology (ASCO) are expected to spark changes in the management of patients with chronic lymphocytic leukemia (CLL) and individuals with cancer of the prostate, breast, or ovaries.

Adding adjuvant chemotherapy to radiation in patients with low-grade glioma improved overall survival by 5.5 years, said Jan Buckner, MD, chair of oncology at Mayo Clinic, Rochester, Minnesota, who presented results from the Radiation Therapy Oncology Group (RTOG) 9802 trial.

First Page Preview View Large
First page PDF preview
First page PDF preview